Personalized vaccine plus immunotherapy for pancreatic cancer after surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had surgery to remove your pancreatic cancer, and the entire tumor was taken out (with or without cancer cells at the edges).
- Your cancer must not have spread to other organs, only to nearby lymph nodes (stage T1-3, N0-2, M0).
- You should be feeling well enough to do daily activities (ECOG score 0 or 1) and have a life expectancy of at least 6 months.
- You cannot have had any previous cancer treatment like chemotherapy, radiation, or immunotherapy for this cancer.
- You must not have a serious autoimmune disease, active infection, or other conditions that could make the vaccine unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of an oncolytic virus (a virus that targets cancer cells), an immunotherapy drug (anti-PD1), and chemotherapy given before surgery for people with borderline resectable or locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make surgery more successful.
This trial tests two different vaccines (GVAX and a mKRAS vaccine) given before and after surgery for pancreatic cancer. Both vaccines are combined with immunotherapy drugs to help your immune system fight the cancer. The goal is to see which vaccine works better and is safe for patients whose tumors can be removed.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.